MedTrace Logo

Effect of Administration of 3rd Generation Cephalosporin on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (CEF-IMPACT)

NCT03922919 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2019-04-22

No results posted yet for this study

Summary

The aim of this study was to compare the frequency of occurrence of digestive carrying of 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R), acquired during hospitalization in one of the participating departments, between patients treated with ceftriaxone and patients treated with cefotaxime

Conditions

  • Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)

Interventions

DRUG

Cefotaxime Injection

Systematic use of cefotaxime.

PROCEDURE

Rectal swab

Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion

DRUG

Cefotaxime/ceftriaxone

ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-03
Primary Completion
2020-04-03
Completion
2020-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03922919 on ClinicalTrials.gov